PPMICell LinesUseAgreement
Irequestaccesstocell linescollectedbyTheParkinson’sProgressionMarkersInitiative(PPMI)forthepurposeofscientificinvestigationandagreetothefollowingterms:
1.Recipientwillreceivede-identifiedcell linesandwillnotattempttoestablishtheidentityoforattempttocontactanyofthePPMIsubjects.
2.Recipientwillnotshareorusethesecell linesbeyondtheusesoutlinedinthisagreementandRecipient’s proposalforaccess.
3.RecipientwillrequireanyoneonRecipient’steamwhoutilizesthesecell linestocomplywiththisCell LinesUseAgreementbysigningthisagreement.
4.Recipientwillaccuratelyprovidetherequestedinformationforpersonswhowillusethesecell linesandtheanalysesthatareplannedusingthesecell lines.
5.Recipientwillrespondpromptlyandaccuratelytoannualrequeststoupdatethisinformation.
6.RecipientwillcomplywithanyrulesandregulationsimposedbyRecipient’sinstitutionanditsIRBinrequestingthesecell lines.
7.Recipient shall not sell or transfer the cell lines and their derivatives.
8.The cell lines and their derivatives must be used for internal research purposes only, defined here as research by Recipientnot conducted to provide a service for commercial gain and executedin compliance with all terms outlined in the Cell Line Vendors Additional Terms of Use document.
9.The cell lines may not be used directly or indirectly to derive or make any human gamete or gamete precursor cell.
10.The cell lines may not be reversed engineered.
11.Recipient may not use the cell lines or their derivatives in humans, in clinical trials, for diagnostic purposes involving human subjects or for any therapeutic use.
12.Cell lines and their derivatives may not be used in the manufacture of any products.
13.Recipient agrees to adhere to any vendor-specific terms required by the manufacturer of the cell lines as outlined in the Cell Line Vendors Additional Terms of Use document.
14.Recipientwillprepare“lay‟abstractstobepostedonthePPMI and/or MJFF websitesofanalysesthatRecipientisperformingwithPPMIcell lines.
15.Recipient acknowledges that researchers who receive approval to access PPMI cell lines will be granted an exception to the standard PPMI Intellectual Property (IP) Policy that prohibits claiming of new IP generated through use of PPMI samples. Further:
a.Any user of cell lines may generate and claim proprietary IP rights on research tools developed therefrom (“Inventor”).
b.IP on compounds developed and/or tested with any research tool created through or from PPMI cell lines in conformity with PPMI IP policies may remain with the Inventor.
16.Recipient will comply with all provisions described in the PPMI Publication Policy, including the following:
a.IfRecipientpublishesabstractsonanalysesofPPMIcell lines,Recipientagreestothefollowing:
- RecipientwillcitePPMIasthesourceofthecell linesandthePPMIfundingsourcesintheabstractasspaceallows.
- Unless the abstract is identified as a Primary Publication (see PPMI Publication Policy), groupauthorshipofPPMIwillnotbecitedintheauthorshiplineoftheabstract.
- RecipientwilluploadabstractsontothePPMIwebsiteforregistereduserstoseeeitherastheyareacceptedoraftertheyarepresented.
b.IfRecipientpublishesmanuscriptsusingPPMIcell lines,Recipientagreestothefollowing:
- Unless manuscript is identified as a Primary Publication (see PPMI Publication Policy), group authorship of PPMI will not be cited in the authorship line of the manuscript.
- Recipient willincludelanguagesimilartothefollowinginthemethodssectionofthemanuscriptsinordertoaccuratelyacknowledgedatagatheringbythePPMIpersonnel.Dependinguponthelengthandfocusofthearticle,itmaybeappropriatetoincludemoreorlessthantheexamplebelow,however,inclusionofsomevariationofthelanguageshownbelowismandatory:
"Cell linesused in the analyses presented in this articlewereobtainedfromtheParkinson’sProgressionMarkersInitiative(PPMI)( linesbutdidnotparticipateintheanalysisorwritingofthisreport.Forup-to-dateinformationonthestudy,visit
- RecipientwillacknowledgefundingbyPPMIinthesupportacknowledgementsectionofthemanuscriptusinglanguagesimilartothefollowing:
“PPMI–apublic-privatepartnership–isfundedbyTheMichaelJ.FoxFoundationforParkinson’sResearchandcorporatesponsors,including[list all PPMI Industry Partners found at
c.Recipientwillsubmitall abstracts and manuscriptstothePPMIDataandPublicationsCommittee(DPC)priortosubmittingtoajournal.Thisreviewwillnotbeascientificreview,butisintendedtoensurethat allitemsin this Section 16abovearecorrectlyimplemented.TheDPCwillmaintainconfidentialityofthemanuscriptandwillcompleteitsreviewwithintwoweeks.
d.Researcherswhopublishorpresentanalysesofcell lineswillmakethesefreelyavailablewithoutchargetotheresearchcommunitythroughthePPMIwebsite,whennotprohibitedbyjournalcopyrighttermsandconditions.
17.Recipientwillsubmita report of completedanalysesusingPPMIcell linestothePPMI Biospecimen Review Committee (BRC).RecipientunderstandsthatBRC reserves the right to deposit these analyses in the PPMI study database for use by the research community.
18.Recipientwillensurethat other InvestigatorswhoutilizePPMIcell linesuseappropriateadministrative,physicalandtechnicalsafeguardstopreventuseofthecell linesotherthanasprovidedforbythisAgreementandoutlinedintheapplicationprotocol.
19.Recipientwillreportanyuseordisclosureofthecell linesnotprovidedforbythisAgreementofwhichRecipientbecomesawarewithin15daysofbecomingawareofsuchuseordisclosure.
20.Recipient acknowledges that MJFF owns the PPMI cell lines and that use of PPMI cell lines by Recipient does not constitute a transfer of ownership rights.
IunderstandthatfailuretoabidebytheseguidelineswillresultinterminationofmyprivilegestoaccessPPMIdataand/orcell lines.
[Investigatorswillbeaskedtosignthisagreementelectronicallyat